Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Low-dose teclistamab in newly diagnosed multiple myeloma patients

View Full Paper
Ask AI
Bookmark
Share

Authors

JMJosé Emiliano Montelongo-CepedaLTLuz TarinDGDavid Gómez‐Almaguer

Discussion

Loading...

Member takes

Overview

Single-arm phase II trial shows 100% complete response rate after low-dose teclistamab in multiple myeloma, suggesting improved safety and efficacy.

Key Points

  • Complete response achieved in all evaluated patients following low-dose teclistamab treatment.
  • Nine patients completed consolidation with teclistamab, resulting in an overall response rate of 100%.
  • Assessment using flow cytometry indicated all patients attained measurable residual disease negativity after therapy.
  • This approach may allow treatment-free periods and reduce the risk of infections associated with prolonged therapy.

Cite This Study

Montelongo-Cepeda et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da95https://doi.org/10.1182/blood-2025-4047
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Teclisito: Low-intensity teclistamab in the outpatient setting for Relapsed/Refractory multiple myeloma2025
  2. 2Real-world efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: Results from 87 patients treated by the polish myeloma group2025
  3. 3Teclistamab induced rapid and deep hematologic response in relapsed/refractory light chain amyloidosis: A multicenter retrospective study2025 · 1 citations
  4. 4Real-world analysis of infection timing and burden in multiple myeloma patients treated with teclistamab2025
  5. 5A phase 2 Study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: The IFM2021-01 teclille trial, cohort a2025 · 12 citations